Cited by 140Antifungal resistance and susceptibilityFungal Infections and StudiesNail Diseases and Treatments

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin: In vitro Bewertung von Voriconazol gegenüber klinischen Isolaten von Hefen, Schimmelpilzen und Dermatophyten im Vergleich mit Itraconazol, Ketoconazol, Amphotericin B und Griseofulvin

Wildfeuer, A., Seidl, H. P., Paule, I., Haberreiter, A.·1998·Mycoses

DOI 10.1111/j.1439-0507.1998.tb00344.x

Open this paper in CoChat — free account

Abstract

Summary. The in vitro activity of voriconazole (UK‐109, 496), a new antifungal triazole derivative, against 650 clinical isolates of yeasts, moulds and dermatophytes was compared with that of itraconazole, ketoconazole, amphotericin B and griseofulvin. The geometric means of the minimum inhibitory concentrations (MICs) of voriconazole were 0.05 μg ml‐1 against yeasts (n= 187), 0.58 μg ml‐1 against moulds (n= 260) and 0.08 μg ml‐1 against dermatophytes (n= 203). The overall activity of voriconazole against yeasts and moulds was good, being similar to that of itraconazole, ketoconazole and amphotericin B. Voriconazole was highly effective against Aspergillus fumigatus (mean MIC 0.23 μg ml‐1) and other Aspergillus species and showed noteworthy activity (mean MICs 0.08‐0.78 μg ml‐1) against emerging and less common clinical isolates of opportunistic moulds, such as Altenaria spp., Cladosporium spp., Acremonium spp., Chrysosporium spp. and Fusarium spp. On the other hand, voriconazole was less active in vitro than the comparative agents studied against various species of zygomycetes, such as Mucor spp., Rhizopus spp. and Absidia spp. Voriconazole and the other two azoles, itraconazole and ketoconazole, were more active than griseofulvin in vitro against most dermatophytes tested. Zusammenfassung. Die In‐vitro‐Aktivität von Voriconazol (UK‐109,496), einem neuen antimy‐kotischen Triazol‐Derivat, wurde gegen 650 klinische Isolate von Hefen, Schimmelpilzen und Dermatophyten mit Itraconazol, Ketoconazol, Amphotericin B und Griseofulvin verglichen. Die mittieren MHK‐Werte (minimalen Hemmkonzentrationen) betrugen gegenüber Hefen 0.05 μg ml‐1 (n= 187), Schimmelpilzen 0.58 μg ml‐1 (n= 260) und Dermatophyten 0.08 μg ml‐1 (n= 203). Insgesamt war die Aktivität von Voriconazol gegen Hefen und Schimmelpilze gut und vergleichbar mit Itraconazol, Ketoconazol und Amphotericin B. Voriconazol war sehr wirksam gegen Aspergillus fumigatus (mittlere MHK 0.23 μg ml‐1) und andere Aspergillus‐Spezies und zeigte ein bemerkenswerte Aktivität (mittlere MHK 0.08‐0.78 μg ml‐1) gegen aufkommende und bisher weniger häufige klinische Isolate opportunistischer Schimmelpilze wie Alternaria spp., Cladosporium spp., Acremonium spp., Chrysosporium spp. und Fusarium spp., Andererseits war Voriconazol in vitro gegen verschiedene Spezies von Zygomyceten wie Mucor spp., Rhizopus spp. und Absidia spp. weniger wirksam als die untersuchten Vergleichssubstanzen. Voriconazol und die anderen beiden Azole, Itraconazol und Ketoconazol, waren in vitro gegen die meisten geprüften Dermatophyten wirksamer als Griseofulvin.

Integrity signals

Registry

Crossref · 10.1111/j.1439-0507.1998.tb00344.x

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Therapeutic Outcome in Invasive Aspergillosis
Denning, D. W. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.3.608 · Cited by 683
Oral Azole Drugs as Systemic Antifungal Therapy
Wood, A. J. J., Como, J. A., & Dismukes, W. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300407 · Cited by 596
Fungal infections in cancer patients: An international autopsy survey
Bodey, G. P., Bueltmann, B., Duguid, W. P., Gibbs, D. L., Hanak, H., Hotchi, M., Mall, G., Martino, P., Meunier, F., Milliken, S., et al. (1992) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01967060 · Cited by 546
NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis
Denning, D. W., Lee, J. Y., Hostetler, J. S., Pappas, P. G., Kauffman, C. A., Dewsnup, D. H., Galgiani, J. N., Graybill, J. R., Sugar, A. M., Catanzaro, A., et al. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90023-x · Cited by 448
A Controlled Trial of Fluconazole or Amphotericin B to Prevent Relapse of Cryptococcal Meningitis in Patients with the Acquired Immunodeficiency Syndrome
Powderly, W. G., Saag, M. S., Cloud, G. A., Robinson, P. A., Meyer, R. D., Jacobson, J. M., Graybill, J. R., Sugar, A. M., McAuliffe, V. J., Follansbee, S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203193261203 · Cited by 351
Non-Candida fungal infections after bone marrow transplantation: Risk factors and outcome
Morrison, V. A., Haake, R. J., & Weisdorf, D. J. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90088-4 · Cited by 214
In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens
Radford, S. A., Johnson, E. M., & Warnock, D. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.841 · Cited by 188
In vitro evaluation of voriconazole against some clinically important fungi
McGinnis, M. R., Pasarell, L., Sutton, D. A., Fothergill, A. W., Cooper, C. R., & Rinaldi, M. G. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1832 · Cited by 132
Antifungal Agents in the 1990s
Kauffman, C. A., & Carver, P. L. (1997) · Drugs · doi:10.2165/00003495-199753040-00001 · Cited by 129

Show all 20 references

Sorted by citations

ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections
Arendrup, M. C., Boekhout, T., Akova, M., Meis, J. F. G. M., Cornely, O. A., & Lortholary, O. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12360 · Cited by 533
Human fusariosis
Dignani, M. C., & Anaissie, E. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00845.x · Cited by 351
In vitro susceptibilities of zygomycetes to conventional and new antifungals
Dannaoui, É. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg020 · Cited by 312
Antifungal drug resistance to azoles and polyenes
Canuto, M. M., & Rodero, F. G. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00371-7 · Cited by 310
In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature
Espinel‐Ingroff, A., Boyle, K., & Sheehan, D. J. (2001) · Mycopathologia · doi:10.1023/a:1010954803886 · Cited by 251
Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies
Karlsson, M. O., Lutsar, I., & Milligan, P. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00751-08 · Cited by 228
“(including Candida krusei and Candida glabrata, which are less susceptible to other azoles), and a broad range of rare and emerging fungal pathogens (with the notable exception of zygomycetes) (3, 12, 14, 24).”
Background
Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: A randomized, double-blind clinical trial
Weschta, M., Rimek, D., Formanek, M., Polzehl, D., Podbielski, A., & Riechelmann, H. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.03.038 · Cited by 216
Amphotericin B nasal lavages: Not a solution for patients with chronic rhinosinusitis
Ebbens, F. A., Scadding, G. K., Badia, L., Hellings, P. W., Jorissen, M., Mullol, J., Cardesín, A., Bachert, C., Zele, T. V., Dijkgraaf, M. G. W., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.07.058 · Cited by 212
In Vitro Activities of 10 Antifungal Drugs against 508 Dermatophyte Strains
Fernández-Torres, B., Carrillo, A., Martin, E., del Palacio, A., Moore, M. K., Valverde, A., Serrano, M. C. L., & Guarro, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2524-2528.2001 · Cited by 164
“(17), it was obtained by testing a large number of species of dermatophytes as they did, while using different test conditions, such as a macrobroth dilution method.”
Background
Novel triazole antifungal agents
Hoffman, H. L., Ernst, E. J., & Klepser, M. E. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.3.593 · Cited by 133
Collaborative Evaluation of Optimal Antifungal Susceptibility Testing Conditions for Dermatophytes
Fernández-Torres, B., Cabañes, F. J., Carrillo‐Muñoz, A. J., Esteban, A., Inza, I., Abarca, M. L., & Guarro, J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.11.3999-4003.2002 · Cited by 126
“In recent years, some authors, possibly encouraged by the development of the above-mentioned reference method, have published various articles wherein several species of dermatophytes have been tested (11, 27, 28, 34).”
Result
New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer
Chiou, C. C., Groll, A. H., & Walsh, T. J. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2-120 · Cited by 124
Voriconazole—a new therapeutic agent with an extended spectrum of antifungal activity
Donnelly, J. P., & Pauw, B. E. D. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00838.x · Cited by 111
“[2], as well as the dimorphic fungi Histoplasma capsulatum, Blastomyces dermatitidis and Coccidioides immitis [3].”
Background
Review of the safety and efficacy of voriconazole
Rathbun, R. C., & Hoffman, H. L. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.3.409 · Cited by 110
“terreus are summarised in Table 3 [69-80].”
New antifungal agents
Gupta, A. K., & Tomas, E. T. (2003) · Dermatologic Clinics · doi:10.1016/s0733-8635(03)00024-x · Cited by 108
“including AmB-resistant clinical isolates [48–53], Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum [54].”
BackgroundResult
Scopulariopsis brevicaulis, a Fungal Pathogen Resistant to Broad-Spectrum Antifungal Agents
Cuenca‐Estrella, M., Gómez‐López, A., Mellado, E., Buitrago, M. J., Monzón, A., & Rodrı́guez-Tudela, J. L. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2339-2341.2003 · Cited by 99
Inhibition of human pathogenic fungi by ethnobotanically selected plant extracts
Ficker, C., Arnason, J. T., Vindas, P. S., Álvarez, L. P., Akpagana, K., Gbéassor, M., de Souza, C., & Smith, M. L. (2003) · Mycoses · doi:10.1046/j.1439-0507.2003.00838.x · Cited by 97
Comparison of In Vitro Activities of 17 Antifungal Drugs against a Panel of 20 Dermatophytes by Using a Microdilution Assay
Favre, B., Hofbauer, B., Hildering, K.-S., & Ryder, N. S. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.10.4817-4819.2003 · Cited by 97
Novel antifungal drugs
DiDomenico, B. (1999) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(99)00009-0 · Cited by 91
Comparison of In Vitro Activities of Voriconazole and Five Established Antifungal Agents against Different Species of Dermatophytes Using a Broth Macrodilution Method
Perea, S. H., Fothergill, A. W., Sutton, D. A., & Rinaldi, M. G. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.1.385-388.2001 · Cited by 91
In vitro activity of antifungals against Zygomycetes
Alastruey‐Izquierdo, A., Castelli, M. V., Cuesta, I., Zaragoza, Ó., Monzón, A., Mellado, E., & Rodríguez-Tudela, J. L. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02984.x · Cited by 83
“In vitro results show that itraconazole is more active against Zygomycetes than voriconazole and that some strains are inhibited by low concentrations of itraconazole [18,43–45].”
Background
Trichosporon beigelii: a life-threatening pathogen in immunocompromised hosts
Erer, B., GALIMBERTI, M., Lucarelli, G. T., Giardini, C., Polchi, P., BARONCIANI, D., Gaziev, J., Angelucci, E., & Izzi, G. C. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702231 · Cited by 82
The effect of topical amphotericin B on inflammatory markers in patients with chronic rhinosinusitis: A multicenter randomized controlled study
Ebbens, F. A., Georgalas, C., Luiten, S., van Drunen, C. M., Badia, L., Scadding, G. K., Hellings, P. W., Jorissen, M., Mullol, J., Cardesín, A., et al. (2009) · The Laryngoscope · doi:10.1002/lary.20064 · Cited by 78
“The applied concentration (100 mg/mL) is approximately 30 to 100 times higher than the minimum inhibitory concentration for all relevant fungi.(13) The study”
Background
Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Ruhnke, M., Cornely, O. A., Schmidt‐Hieber, M., Alakel, N., Boell, B., Buchheidt, D., Christopeit, M., Hasenkamp, J., Heinz, W., Hentrich, M., et al. (2020) · Mycoses · doi:10.1111/myc.13082 · Cited by 76
Determination of voriconazole in aqueous humor by liquid chromatography–electrospray ionization-mass spectrometry
Zhou, L., Glickman, R. D., Chen, N., Sponsel, W. E., Graybill, J. R., & Lam, K. (2002) · Journal of Chromatography B · doi:10.1016/s1570-0232(02)00344-6 · Cited by 73
The Exciting Future of Antifungal Therapy
Neely, M. N., & Ghannoum, M. A. (2000) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960000395 · Cited by 71
An Overview of Antifungal Drugs and Their Use for Treatment of Deep and Superficial Mycoses in Animals
Hector, R. F. (2005) · Clinical Techniques in Small Animal Practice · doi:10.1053/j.ctsap.2005.07.005 · Cited by 71
Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope ® registry
Jenks, J. D., Seidel, D., Cornely, O. A., Chen, W., van Hal, S. J., Kauffman, C. A., Miceli, M. H., Heinemann, M., Christner, M., Jover-Sáenz, A., et al. (2020) · Mycoses · doi:10.1111/myc.13067 · Cited by 63
The synthesis of xanthones, xanthenediones, and spirobenzofurans: Their antibacterial and antifungal activity
Omolo, J. J., Johnson, M. M., van Vuuren, S. F., & de Koning, C. B. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.09.088 · Cited by 59
Synthesis and Antifungal Activities of Novel 2-Aminotetralin Derivatives
Bin, Y., Ji, H., Cao, Y., Zhou, Y., Zhu, J., Lü, J., Li, Y., Chen, J., Zheng, C., Jiang, Y., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0701167 · Cited by 59
Emerging azole antifungals
Chen, A. L., & Sobel, J. D. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.1.21 · Cited by 60
“generate high voriconazole mean inhibitory concentrations (MIC values) [59-61].”
Background
Synergistic antifungal activity of statin–azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-bioassays and ergosterol quantification
Cabral, M. E., Figueroa, L. I. C., & Fariña, J. I. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2012.09.006 · Cited by 54
Phaeohyphomycosis due to Alternaria species in transplant recipients
Boyce, R., Deziel, P. J., Otley, C. C., Wilhelm, M. P., Eid, A. J., Wengenack, N. L., & Razonable, R. R. (2009) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2009.00482.x · Cited by 57
In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis
Carrillo‐Muñoz, A. J., Giusiano, G., Guarro, J., Quindós, G., Guardia, C., del Valle, O., Rodríguez, V., Estivill, D., & Cárdenes, C. D. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.04.004 · Cited by 54
Species Distribution and Antifungal Susceptibility Profile of Oral Candida Isolates from HIV-infected Patients in the Antiretroviral Therapy Era
Costa, C. R., Lemos, J. A., Passos, X. S., de Araújo, C. R., Cohen, A. J., Souza, L. K. H. E., & Silva, M. D. R. R. (2006) · Mycopathologia · doi:10.1007/s11046-006-0032-y · Cited by 53
“These results agree with those ones verified by other researchers that showed that voriconazole obtained by estrutural fluconazole modification presents a big action spectrum and has been considered more effective against yeasts of the genus Candida [33, 34].”
Result
Postoperative application of amphotericin B nasal spray in chronic rhinosinusitis with nasal polyposis, with a review of the antifungal therapy
Gerlinger, I., Fittler, A., Fonai, F., Patzkó, Á., Mayer, A., & Botz, L. (2008) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-008-0836-0 · Cited by 51
Imidazole Analogues of Fluoxetine, a Novel Class of Anti-CandidaAgents
Silvestri, R., Artico, M., Regina, G. L., Pasquali, A. D., Martino, G. D., D’Auria, F. D., Nencioni, L., & Palamara, A. T. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049856v · Cited by 50
Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy
Trinh, J. V., Steinbach, W. J., Schell, W. A., Kurtzberg, J., Giles, S. S., & Perfect, J. R. (2003) · Medical Mycology · doi:10.1080/369378031000137369 · Cited by 49
Two case reports: Fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient
Mattner, F., Weißbrodt, H., & Strueber, M. (2004) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540410019408 · Cited by 49
Voriconazole Treatment of DisseminatedPaecilomycesInfection in a Patient with Acquired Immunodeficiency Syndrome
Martin, C. A., Roberts, S., & Greenberg, R. N. (2002) · Clinical Infectious Diseases · doi:10.1086/342302 · Cited by 48
Disseminated Geotrichum candidum infection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature
Henrich, T. J., Marty, F. M., Milner, D. A., & Thorner, A. R. (2009) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2009.00418.x · Cited by 47
Fungicidal activities of commonly used disinfectants and antifungal pharmaceutical spray preparations against clinical strains of Aspergillus and Candida species
Gupta, A. K., Ahmad, I., & Summerbell, R. C. (2002) · Medical Mycology · doi:10.1080/mmy.40.2.201.208 · Cited by 47
Antifungal Pharmacodynamics: Review of the Literature and Clinical Applications
Dodds, E. S., Drew, R. H., & Perfect, J. R. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.17.1335.34901 · Cited by 46
In Vitro Antifungal Susceptibilities of Uncommon Basidiomycetous Yeasts
Serena, C., Pastor, F. J., Ortoneda, M., Capilla, J., NOLARD, N., & Guarro, J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2724-2726.2004 · Cited by 45
Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates
Arıkan, S., & Hasçelik, G. (2002) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00376-0 · Cited by 44
Effect of Nasal Antifungal Therapy on Nasal Cell Activation Markers in Chronic Rhinosinusitis
Weschta, M., Rimek, D., Formanek, M., Podbielski, A., & Riechelmann, H. (2006) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.132.7.743 · Cited by 44
“The appliedamphotericinBconcentrationof3mg/mLiswellabove the minimum inhibitory concentrations for common nasal fungi, and resistance to this drug is rare.(16) Amphotericin B was used as a nasal spray for several reasons.”
Background
Canine and feline dermatophytosis due to Microsporum gypseum: A retrospective study of clinical data and therapy outcome with griseofulvin
Nardoni, S., Mugnaini, L., Papini, R. A., Fiaschi, M., & Mancianti, F. (2013) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2013.05.005 · Cited by 43
“Studies dealing with the in vitro sensitivity of this dermatophyte to common antimycotic drugs show the effectiveness of itraconazole and terbinafine [14], of terbinafine in comparison with griseofulvin [16], of itraconazole in comparison with ketoconazole and griseofulvin [28], while five out of five M.”
Result
Measurement of voriconazole in serum and plasma
Langman, L. J., & Boakye‐Agyeman, F. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.07.024 · Cited by 43
“024 significant clinical isolates like Aspergillus, Candida, Scedosporium and Fusarium [4–7].”
Background
Onychomycosis caused by Alternaria spp. in Tuscany, Italy from 1985 to 1999
Romano, C., Paccagnini, E., & Difonzo, E. M. (2001) · Mycoses · doi:10.1046/j.1439-0507.2001.00622.x · Cited by 41
In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole
Gómez‐López, A. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.6.919 · Cited by 40
Human Hyalohyphomycoses: A Review of Human Infections Due toAcremoniumspp.,Paecilomycesspp.,Penicilliumspp., andScopulariopsisspp.
Schinabeck, M. K., & Ghannoum, M. A. (2003) · Journal of Chemotherapy · doi:10.1179/joc.2003.15.supplement-2.5 · Cited by 38
Disseminated adiaspiromycosis: case report of a liver transplant patient with human immunodeficiency infection, and literature review
Pelegrín, I., Ayats, J., Xiol, X., Cuenca‐Estrella, M., Jucglá, A., Boluda, S., Sabé, N., Rafecas, A., Gudiol, F., & Cabellos, C. (2011) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2011.00611.x · Cited by 37
Aspergillus pragensis sp. nov. discovered during molecular reidentification of clinical isolates belonging to Aspergillus section Candidi
Hubka, V., Lysková, P., Frisvad, J. C., Peterson, S. W., Skořepová, M., & Kolařík, M. (2014) · Medical Mycology · doi:10.1093/mmy/myu022 · Cited by 37
“[41] and Ahmadi et al.”
Effects of disinfectants on inactivation of mold spores relevant to the food industry: a review
Visconti, V., Coton, E., Rigalma, K., & Dantigny, P. (2021) · Fungal Biology Reviews · doi:10.1016/j.fbr.2021.09.004 · Cited by 34
Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes
Simitsopoulou, M., Roilides, E., Maloukou, A., Gil‐Lamaignere, C., & Walsh, T. J. (2007) · Mycoses · doi:10.1111/j.1439-0507.2007.01457.x · Cited by 34
1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, New Imidazoles with Potent Activity againstCandida albicansand Dermatophytes. Synthesis, Structure−Activity Relationship, and Molecular Modeling Studies
Regina, G. L., D’Auria, F. D., Tafi, A., Piscitelli, F., Olla, S., Caporuscio, F., Nencioni, L., Cirilli, R., Torre, F. L., de Melo, N. R., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800009r · Cited by 33
In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula
Serena, C. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki131 · Cited by 33
“However, these drugs have repeatedly failed against infections caused by Trichosporon species, Rhodotorula glutinis and Sporobolomyces salmonicolor.(3,5) Such a limitation, associated with amphotericin B toxicity, makes interesting the evaluation of the combination of new and conventional drugs to obtain better clinic…”
Background
An updated list of eumycetoma causative agents and their differences in grain formation and treatment response
van de Sande, W. W. J., & Fahal, A. H. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00034-23 · Cited by 31
Species of Aspergillus section Aspergillus from clinical samples in the United States
Siqueira, J. P. Z., Sutton, D. A., Gené, J., García, D., Wiederhold, N. P., & Guarro, J. (2017) · Medical Mycology · doi:10.1093/mmy/myx085 · Cited by 31
New and Investigational Triazole Agents for the Treatment of Invasive Fungal Infections
Sarro, A. D., Camera, E. L., & Fera, M. T. (2008) · Journal of Chemotherapy · doi:10.1179/joc.2008.20.6.661 · Cited by 30
Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis
Eisen, D. P., & Robson, J. (2004) · Mycoses · doi:10.1111/j.1439-0507.2004.00959.x · Cited by 31
Antifúngicos disponibles para el tratamiento de las micosis ungueales
Carrillo‐Muñoz, A. J., Tur‐Tur, C., Hernández-Molina, J. M., Santos, P., Cárdenes, D., & Giusiano, G. (2010) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2010.01.007 · Cited by 30
New developments in chemotherapy for non-invasive fungal infections
Hossain, M. A., & Ghannoum, M. A. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.8.1501 · Cited by 30
“Voriconazole also showed activity against dermatophytes, the mean MIC being lower than that of griseofulvin and ketoconazole but higher than that of itraconazole [57].”
Background
Design, synthesis, and antifungal activities of novel triazole derivatives containing the benzyl group
Yu, S., Xu, K., Huang, L., Xu, Z. Q., Wang, Y., Bai, G.-J., Wu, Q., Wang, X., & Jiang, Y. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s74989 · Cited by 32
“One of the principal problems in the treatment of Candida albicans infections is the spread of antifungal drug resistance, mainly in patients chronically subjected to antimycotic therapy such as HIV-infected people.(7,8) More recently, there has been a development in the number of antifungal drugs available.”
Triazole derivatives with improved in vitro antifungal activity over azole drugs
Yu, S., Chai, X., Wang, Y., Cao, Y., Zhang, J., Wu, Q., Zhang, D., Jiang, Y., Yan, T., & Sun, Q. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s58680 · Cited by 29
“One of the principal problems in the treatment of Candida albicans infections is the spread of antifungal drug resistance, mainly in patients chronically subjected to antimycotic therapy such as HIV-infected individuals.(3,4) More recently, there has been an expansion in the number of antifungal drugs available.”
New agents for the treatment of systemic fungal infections – current status
Rex, J. H., & Arıkan, S. (2002) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.7.1.3 · Cited by 29
Synthesis and Anti‐Candida Potential of Certain Novel 1‐[(3‐Substituted‐3‐phenyl)propyl]‐1H‐imidazoles
Aboul-Enein, M. N., El‐Azzouny, A. A., Attia, M. I., Saleh, O. A., & Kansoh, A. L. (2011) · Archiv der Pharmazie · doi:10.1002/ardp.201000224 · Cited by 28
Paecilomyces variotii fungemia in a patient with multiple myeloma: case report and literature review
Salle, V., Lecuyer, E., Chouaki, T., Lescure, F.-X., Smaïl, A., Vaidie, A., Dayen, C., Schmit, J., Ducroix, J. P., & Douadi, Y. (2004) · Journal of Infection · doi:10.1016/j.jinf.2004.09.006 · Cited by 28
Synthesis of some Mannich base derivatives and their antimicrobial activity study
Idhayadhulla, A., Surendrakumar, R., Nasser, A. J. A., Selvin, J., & Manilal, A. (2010) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2010.12.025 · Cited by 28
Zygomycosis:Two Case Reports and Review of Reported Cases in the Literature in Japan
Mori, T., Egashira, M., Kawamata, N., Oshimi, K., Nakamura, K., Oguri, T., Aida, H., Hiruma, A., & 一戸, 正. (2003) · Nippon Ishinkin Gakkai Zasshi · doi:10.3314/jjmm.44.163 · Cited by 28
Polyphasic data support the splitting of Aspergillus candidus into two species; proposal of Aspergillus dobrogensis sp. nov.
Hubka, V., Nováková, A., Jurjević, Ž., Sklenář, F., Frisvad, J. C., Houbraken, J. A. M. P., Arendrup, M. C., Jørgensen, K. M., Siqueira, J. P. Z., Gené, J., et al. (2018) · INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY · doi:10.1099/ijsem.0.002583 · Cited by 27
New agents for treatment of systemic fungal infections
Arıkan, S., & Rex, J. H. (2000) · Emerging Drugs · doi:10.1517/14728214.5.2.135 · Cited by 26
“By contrast, it achieves high concentrations in fatty tissues and purulent exudates [91,92].”
Background
Newer antifungal therapy for emerging fungal pathogens
Steinbach, W. J., & Perfect, J. R. (2003) · International Journal of Infectious Diseases · doi:10.1016/s1201-9712(03)90037-3 · Cited by 27
Synthesis and pharmacological properties of N‐substituted‐N′‐(4,6‐dimethylpyrimidin‐2‐yl)‐thiourea derivatives and related fused heterocyclic compounds
Saeed, S., Rashid, N., Jones, P. G., & Tahir, A. (2010) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.510 · Cited by 25
Synthesis and in Vitro and in Vivo Structure−Activity Relationships of Novel Antifungal Triazoles for Dermatology
Meerpoel, L., Backx, L. J. J., der Veken, L. J. E. V., Heeres, J., Corens, D., Groot, A. D., Odds, F. C., Gerven, F. V., Woestenborghs, F., Breda, A. V., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0494772 · Cited by 25
Actividad in vitro de anfotericina B, itraconazol y voriconazol frente a 20 especies de Aspergillus empleando el método de microdilución Sensititre®
García-Martos, P., García-Agudo, L., Jl, G. C., Ruiz-Aragón, J., Saldarreaga, A., & Marín, P. (2005) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13070403 · Cited by 24
In vitro efficacy of a buffered chelating solution as an antimicrobial potentiator for antifungal drugs against fungal pathogens obtained from horses with mycotic keratitis
Weinstein, W. L., Moore, P. A., Sánchez, S., Dietrich, U. M., Wooley, R. E., & Ritchie, B. W. (2006) · American Journal of Veterinary Research · doi:10.2460/ajvr.67.4.562 · Cited by 24
Multilocus Phylogeny and Antifungal Susceptibility of Aspergillus Section Circumdati from Clinical Samples and Description of A. pseudosclerotiorum sp. nov
Siqueira, J. P. Z., Sutton, D. A., Gené, J., García, D., Wiederhold, N. P., Peterson, S. W., & Guarro, J. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.02012-16 · Cited by 23
“In contrast, amphotericin B shows limited activity against species in this section (18, 23, 24), particularly against A.”
Background
Successful treatment of resistant onychomycosis with voriconazole in a liver transplant patient
Nofal, A., Fawzy, M. M., & El‐Hawary, E. E. (2020) · Dermatologic Therapy · doi:10.1111/dth.14014 · Cited by 23
Antifungal susceptibility profile of clinical Alternaria spp. identified by molecular methods
Alastruey‐Izquierdo, A., Cuesta, I., Ros, L., Mellado, E., & Rodríguez-Tudela, J. L. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr365 · Cited by 22
Trends in the treatment of dermatophytosis.
del Palacio, A., Garau, M. V., González-Escalada, A., Calvo, M. T., Kushwaha, R. K. S., & Guarro, J. (2000) · Cited by 22
Actividad antifúngica in vitro de voriconazol contra dermatofitos y aislamientos superficiales de Scopulariopsis brevicaulis
Carrillo‐Muñoz, A. J., Cárdenes, C. D., Carrillo-Orive, B., Rodríguez, V., del Valle, O., Casals, J. B., Ezkurra, P. A., & Quindós, G. (2005) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(05)70019-x · Cited by 22
Unusual dermatomycoses caused by Nannizzia nana: the geophilic origin of human infections
Gnat, S., Łagowski, D., Nowakiewicz, A., & Dyląg, M. (2020) · Infection · doi:10.1007/s15010-020-01416-5 · Cited by 21
Central nervous system infection due to Penicillium chrysogenum
Kantarcıoğlu, A. S., Apaydın, H., Yücel, A., de Hoog, S., Samson, R. A., Vural, M., & Özekmekçi, S. (2004) · Mycoses · doi:10.1111/j.1439-0507.2004.00974.x · Cited by 20
In vitro Activity of Sertaconazole against Dermatophyte Isolates with Reduced Fluconazole Susceptibility
Carrillo‐Muñoz, A. J., Fernández-Torres, B., Cárdenes, D., & Guarro, J. (2003) · Chemotherapy · doi:10.1159/000072449 · Cited by 20
Les champignons des genres Acremonium, Beauveria, Chrysosporium, Fusarium, Onychocola, Paecilomyces, Penicillium, Scedosporium et Scopulariopsis responsables de hyalohyphomycoses
Hocquette, A., Grondin, M., Bertout, S., & Mallié, M. (2005) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2005.06.002 · Cited by 18
2‐substituted 4H‐[1,3]thiazolo[3,2‐a][1,3,5]triazine‐4‐thiones: Synthesis, crystal structure, and antifungal activity
Saeed, S., Rashid, N., Jones, P. G., & Yunas, U. (2010) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.439 · Cited by 18
Topical 5% Natamycin With Oral Ketoconazole in Filamentous Fungal Keratitis
Rajaraman, R., Bhat, P., Vaidee, V., Maskibail, S., Raghavan, A., Sivasubramaniam, S., & Prajna, N. V. (2014) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000035 · Cited by 17
Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology
Lal, N., Jangir, S., Bala, V., Mandalapu, D., Sarswat, A., Kumar, L., Jain, A., Kumar, L., Kushwaha, B., Pandey, A. K., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.012 · Cited by 17
New options for the treatment of invasive fungal infections
Rubin, Z., & Somani, J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.02.020 · Cited by 14
Dermatophytosis caused by Nannizzia nana in two siblings
Bonifáz, A., Córdoba-García, B., Simancas-Llanos, T., Hernández, M. A. L., Martínez-Herrera, E. O., & Tirado‐Sánchez, A. (2019) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2018.02.003 · Cited by 14
A case of peritonitis caused by Rhizopus microsporus
Monecke, S., Hochauf-Stange, K., Gottschlich, B., & Ehricht, R. (2006) · Mycoses · doi:10.1111/j.1439-0507.2006.01190.x · Cited by 14
Comparative analysis of whole genomes and transcriptomes of Microsporum canis from invasive dermatophytosis and tinea capitis
Wang, R., Liu, W., Liu, X., Wan, Z., de Hoog, S., Li, R., & Song, Y. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2219346 · Cited by 13
Determination of Voriconazole Concentrations in Serum by GC‐MS
Smith, A., & Leung‐Pineda, V. (2015) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.21871 · Cited by 13
New imidazole derivatives of 2(3H)‐benzazolones as potential antifungal agents
Petrov, O., Gerova, M. S., Petrova, K. V., & Ivanova, Y. (2009) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.11 · Cited by 13
Molecular identification of phaeohyphomycosis due to Alternaria infectoria in a patient with acute myeloid leukemia—a case report
Leahy, T. R., Punnett, A., Richardson, S. E., Gharabaghi, F., & Wadhwa, A. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.09.019 · Cited by 12
Synthesis of novel Bis-1,2,4-Triazolo[3,4-b][1,3,4]Thiadiazines from natural camphoric acid as potential anti-candidal agents
Ouf, S. A., Gomha, S. M., Farag, B., Zaki, M. E. A., Ewies, M. M., Sharawy, I. A. A., Khalil, F. O., & Mahmoud, H. K. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101406 · Cited by 11
Actividad in vitro de voriconazol y otros tres antifúngicos frente a dermatofitos
Serrano, M. D. C., Chávez-Caballero, M., Valverde, A., Claro, R. M., Pemán, J., & Martín‐Mazuelos, E. (2003) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(03)72992-9 · Cited by 11
Systemic Infection due to Acremonium after Allogeneic Peripheral Blood Stem Cell Transplantation
Yamazaki, R., Mori, T., Aisa, Y., Nakazato, T., Mihara, A., Ikeda, Y., & Okamoto, S. (2006) · Internal Medicine · doi:10.2169/internalmedicine.45.1827 · Cited by 10
Soft-tissue infection withAbsidia corymbiferaand kidney complications in an AIDS patient
Righi, E., Giacomazzi, C., Bassetti, M., Bisio, F., Soro, O., McDermott, J. L., Varnier, O. E., Ratto, S., & Viscoli, C. (2007) · Medical Mycology · doi:10.1080/13693780701435358 · Cited by 10

Authors: Wildfeuer, A., Seidl, H. P., Paule, I., & Haberreiter, A.
Affiliations: Pfizer (United States) (US)
Technical University of Munich (DE)
Corresponding author: Wildfeuer, A.
Venue: Mycoses
Publisher: Wiley
Published: 1998-09
Volume: 41
Issue: 7-8
Pages: 309-319
ISSN: 0027-5557 (ISSN-L)
0933-7407
1439-0507
DOI: 10.1111/j.1439-0507.1998.tb00344.x
OpenAlex: W1992535097
Cited by: 140
References: 20
Citations by year: 2024: 5 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 2 · 2015: 7 · 2014: 5 · 2013: 3 · 2012: 2
FWCI: 4.72
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 3888 d)
Locations: Mycoses (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
Keywords: voriconazole, antifungal activity, yeast, molds, dermatophytes, itraconazole, ketoconazole, amphotericin B, griseofulvin, minimum inhibitory concentration, Aspergillus fumigatus, Zygomycetes, triazole antifungals, clinical isolates
MeSH terms: Amphotericin B, Antifungal Agents, Fungi, Griseofulvin, Humans, Ketoconazole, Microbial Sensitivity Tests, Mycoses, Pyrimidines, Triazoles, Itraconazole, Voriconazole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks